Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCENT-2: DN-101 plus weekly docetaxel in metastatic androgen-independent (castration-resistant) prostate cancer
2006-001702-88Phase 3Active
- Sponsor
- Novacea, Inc.
- Start
- May 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of calcitriol in prostate cancer (PCa) (2 arms), sponsored by Novacea, Inc. Primary endpoint: Overall survival. Started May 2006; status: active.
02
Drugs
calcitriol
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2006-001702-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001702-88.